tirzepatide - medicine shortage information

Back to ALL shortages and discontinuations    Back to CRITICAL shortages and discontinuations

If you are having difficulty obtaining a medicine that has been prescribed to you, talk to your doctor or pharmacist to discuss suitable options to continue your care.

More information about medicine shortages and how to access alternative medicines is available at the Medicine Shortages hub

Product details Supply Impact Dates Further Details
MOUNJARO tirzepatide 10 mg/0.5 mL solution for injection vial
AUST R: 407053
Active ingredients:
tirzepatide

Dosage form:
Injection, solution

Sponsor:
Eli Lilly Australia Pty Ltd

Phone:
1800 454 559

From
22 Nov 2023
to
31 Aug 2025

Shortage status:
Current

Availability:
Unavailable

Reason:
Commercial Changes / Commercial viability

Management action:
An unregistered product has been approved for supply under Section 19A. See the website: https://www.tga.gov.au/ws-sl9a-index and search for the active ingredient. A TGA web alert is available at: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/shortage-mounjaro-tirzepatide-injections

MOUNJARO tirzepatide 12.5 mg/0.5 mL solution for injection vial
AUST R: 407052
Active ingredients:
tirzepatide

Dosage form:
Injection, solution

Sponsor:
Eli Lilly Australia Pty Ltd

Phone:
1800 454 559

From
22 Nov 2023
to
31 Aug 2025

Shortage status:
Current

Availability:
Unavailable

Reason:
Commercial Changes / Commercial viability

Management action:
An unregistered product has been approved for supply under Section 19A. See the website: https://www.tga.gov.au/ws-sl9a-index and search for the active ingredient. A TGA web alert is available at: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/shortage-mounjaro-tirzepatide-injections

MOUNJARO tirzepatide 15 mg/0.5 mL solution for injection vial
AUST R: 407054
Active ingredients:
tirzepatide

Dosage form:
Injection, solution

Sponsor:
Eli Lilly Australia Pty Ltd

Phone:
1800 454 559

From
22 Nov 2023
to
31 Aug 2025

Shortage status:
Current

Availability:
Unavailable

Reason:
Commercial Changes / Commercial viability

Management action:
An unregistered product has been approved for supply under Section 19A. See the website:
https://www.tga.gov.au/ws-sl9a-index and search for the active ingredient. A TGA web alert is available at: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/shortage-mounjaro-tirzepatide-injections

MOUNJARO tirzepatide 2.5 mg/0.5 mL solution for injection vial
AUST R: 407055
Active ingredients:
tirzepatide

Dosage form:
Injection, solution

Sponsor:
Eli Lilly Australia Pty Ltd

Phone:
1800 454 559

From
22 Nov 2023
to
31 Aug 2025

Shortage status:
Current

Availability:
Unavailable

Reason:
Commercial Changes / Commercial viability

Management action:
An unregistered product has been approved for supply under Section 19A. See the website: https://www.tga.gov.au/ws-sl9a-index and search for the active ingredient. A TGA web alert is available at: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/shortage-mounjaro-tirzepatide-injections

MOUNJARO tirzepatide 5 mg/0.5 mL solution for injection vial
AUST R: 407050
Active ingredients:
tirzepatide

Dosage form:
Injection, solution

Sponsor:
Eli Lilly Australia Pty Ltd

Phone:
1800 454 559

From
22 Nov 2023
to
31 Aug 2025

Shortage status:
Current

Availability:
Unavailable

Reason:
Commercial Changes / Commercial viability

Management action:
An unregistered product has been approved for supply under Section 19A. See the website: https://www.tga.gov.au/ws-sl9a-index and search for the active ingredient. A TGA web alert is available at: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/shortage-mounjaro-tirzepatide-injections

MOUNJARO tirzepatide 7.5 mg/0.5 mL solution for injection vial
AUST R: 407051
Active ingredients:
tirzepatide

Dosage form:
Injection, solution

Sponsor:
Eli Lilly Australia Pty Ltd

Phone:
1800 454 559

From
22 Nov 2023
to
31 Aug 2025

Shortage status:
Current

Availability:
Unavailable

Reason:
Commercial Changes / Commercial viability

Management action:
An unregistered product has been approved for supply under Section 19A. See the website: https://www.tga.gov.au/ws-sl9a-index and search for the active ingredient. A TGA web alert is available at: https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/shortage-mounjaro-tirzepatide-injections